As described by Gerke et al. [6], in approximately 50% of PCA cases, a chromosomal rearrangement that forms a chimeric oncogene through fusion of TMPRSS2 with ERG (TMPRSS2:ERG or T2E) is present, which may exploit different gene signatures or pathways to promote the malignancy of PCA [6,24,25]. The gene discussed is TMPRSS2; the disease is posterior cortical atrophy.